This study involving expanded-access trial of Drug X in patients infected with HIV in order to make study drug available to patients who failed combination therapy with commercially available antiretroviral agents and who have limited treatment options. Due to its global reach and extensive experience, Quintiles successfully managed 830 sites in 32 countries and recruited 14,521 patients. Also, Quintiles’ efficient project management resulted in a 10% reduction in cost from original budget estimates. Read the case study to learn more.
White Paper February 01, 2011